US Clinical Trial of New Cervical Cancer Detection System to Begin

Publication
Article
OncologyONCOLOGY Vol 12 No 10
Volume 12
Issue 10

NetMed, Inc., a developer and marketer of medical and health-related technologies, announced the commencement of a multicenter US clinical trial of the PAPNET cervical cancer detection system as a primary screening test for Pap smears. The

NetMed, Inc., a developer and marketer of medical and health-related technologies, announced the commencement of a multicenter US clinical trial of the PAPNET cervical cancer detection system as a primary screening test for Pap smears. The trial is being sponsored by Neuromedical Systems, Inc., developer of the PAPNET system, which expects to complete the trial in early 1999.

The clinical trial is expected to demonstrate substantially improved specificity and sensitivity for both conventionally prepared Pap smears and liquid-based preparations, when compared to current manual screening methods.

"This is a significant milestone for the technology and our business," stated David J. Richards, president and CEO of NetMed. "NSI’s worldwide results to date with primary screening give us optimism that this trial will prove successful.

Articles in this issue
Non-Hodgkin’s Lymphoma: Approaches to Current Therapy
Blood and Marrow Transplantation in Relapsed or Refractory Non-Hodgkin’s Lymphoma
Newer Treatments for Non-Hodgkin’s Lymphoma: Monoclonal Antibodies
Establishing the Diagnosis of Lymphoma: From Initial Biopsy to Clinical Staging
Current Approaches to Therapy for Indolent Non-Hodgkin's Lymphoma
Management of Intermediate-Grade Lymphomas
Management of High-Grade Lymphomas
Management of Mantle Cell Lymphoma
Overview of Prognostic Factors in Non-Hodgkin’s Lymphoma
New Biological Markers May Accurately Predict Prognosis in Head and Neck Cancer Patients
Silicone Breast Implants: An Oncologic Perspective
US Clinical Trial of New Cervical Cancer Detection System to Begin
Novel Form of Vitamin K May Stop Liver Cancer Cell Growth
Red Cross Launches First Virus-Inactivated Blood Component
Does Pelvic Irradiation Play a Role in the Management of Prostate Cancer?
Recent Videos
A prospective trial may help affirm ctDNA as a non-invasive option of predicting responses to radiotherapy among those with gynecologic cancers.
ctDNA reductions or clearance also appeared to correlate with a decrease in disease burden during the pre-boost phase of radiotherapy.
Investigators evaluated ctDNA as a potentially noninvasive method to predict response to radiotherapy among those with gynecologic malignancies.
The Foundation for Women’s Cancer provides multicultural resources for patients with gynecologic cancers to help address gaps in care.
Ginger J. Gardner, MD, FACOG, addresses the growing uterine cancer cases among patients in the United States and the need for greater genetic testing.
Ginger J. Gardner, MD, FACOG, discussed the state of gynecologic cancers and her role in empowering research, education, and awareness surrounding them.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Related Content
Data from KEYNOTE-868 and KEYNOTE-A18 support the approval of pembrolizumab-based therapy in endometrial and cervical cancer, respectively.

Pembrolizumab Regimens Earn European Approvals in Gynecologic Cancers

Russ Conroy
October 24th 2024
Article

Data from KEYNOTE-868 and KEYNOTE-A18 support the approval of pembrolizumab-based therapy in endometrial and cervical cancer, respectively.

The FDA approval of pembrolizumab plus chemoradiation benefits patients with stage III to IVA cervical cancer based on findings from the KEYNOTE-A18 trial, according to Jyoti S. Mayadev, MD.

Jyoti S. Mayadev, MD, on Pembrolizumab/CRT FDA Approval in Cervical Cancer

Jyoti Mayadev, MD
January 22nd 2024
Podcast

The FDA approval of pembrolizumab plus chemoradiation benefits patients with stage III to IVA cervical cancer based on findings from the KEYNOTE-A18 trial, according to Jyoti S. Mayadev, MD.

Subgroup data indicate a positive efficacy trend for TG4001 plus avelumab among patients with cervical cancer.

Cancer Vaccine Combo Does Not Improve PFS in Cervical/Anogenital Tumors

Russ Conroy
October 15th 2024
Article

Subgroup data indicate a positive efficacy trend for TG4001 plus avelumab among patients with cervical cancer.

Pharmaceutical, gynecologic oncology, and physician perspectives shed light on potentially mitigating the ongoing carboplatin and cisplatin shortages’ effects on cancer care in the United States.

Navigating the Impact of Chemotherapy Shortages on Cancer Care and Finances

Michael Ganio, PharmD, MS, BCPS, FASHP;Brian Slomovitz, MD;Lucio Gordan, MD
September 18th 2023
Podcast

Pharmaceutical, gynecologic oncology, and physician perspectives shed light on potentially mitigating the ongoing carboplatin and cisplatin shortages’ effects on cancer care in the United States.

Expert Commentary on the Product Profile of Tisotumab Vedotin in Cervical Cancer

Expert Commentary on the Product Profile of Tisotumab Vedotin in Cervical Cancer

Laura Bucher-Bailey, PharmD
September 25th 2024
Article

Laura Bucher-Bailey, PharmD, discussed the approval of tisotumab vedotin-tftv for patients with recurrent or metastatic cervical cancer who have had progression after chemotherapy.

Improving Sexual Health After Gynecological Cancer Is a Multifaceted Approach

Improving Sexual Health After Gynecological Cancer Is a Multifaceted Approach

Ariana Pelosci;Gina Mauro
September 20th 2024
Article

Pluta Cancer Center clinicians discussed how to improve sexual health outcomes for patients diagnosed with gynecological cancer.